At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,202 enrolled
Drug / intervention
LY2189265 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin
In Brief
A Phase 3 clinical trial evaluating LY2189265, Sitagliptin, and 3 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 1,202 participants across 99 sites in 13 countries.
Detailed Summary
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCanada, France, Germany, India, Mexico, Poland, Puerto Rico, Romania, Russia, South Korea, Spain, Taiwan, United States
CollaboratorsUnited BioSource, LLC, Tessella Inc., Berry Consultants
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionJun 2011
Study CompletionJul 2012
TodayJul 2026
First PostedAug 14, 2008
Enrollment StartAug 1, 2008
Primary CompletionJun 1, 2011
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago
Interventions
LY2189265drug
Sitagliptindrug
Placebo solutiondrug
Placebo tabletdrug
Metformindrug